Clinical Trial Update: Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of an allogeneic CD19-targeting CAR-γδT cell therapy (QH103E) for relapsed/refractory non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• QH103E

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Non-hodgkin Lymphoma,B Cell | Phase 1, Phase 2 | Status: RECRUITING